Beck KR, Kim NJ, Khalili M

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 413-418
Archivo PDF: 153.79 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300.

2. Razavi H, ElKhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.

3. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014; 109: 1576-84.

4. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.

5. Schaeffer S, Khalili M. Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. Ann Hepatol 2015; 14(2): 234-42.

6. Brau N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 2006; 13: 242-9.

7. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.

8. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-8.

9. Moyer, VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: a U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-57.

10. Blumenthal D. Health care coverage under the Affordable Care Act - A progress report. N Engl J Med 2014; 371: 275- 81.

11. Surjadi M, Torreullas C, Ayala C, Yee HF Jr., Khalili M. Formal patient education improves patients' knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011; 56: 213-9.

12. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013; 33: 999-1007.

13. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert- Bismut F, Naveau S, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7(40).

14. AASLD-IDSA HCV Guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, man- aging, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54

15. Beck KB, Kim N, Khalili M. Sofosbuvir-containing regimens for chronic hepatitis C are successful in the safety-net population: A real world experience. Dig Dis Sci 2016; 61: 3602.

16. Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, et al. Safety and efficacy of ledipasvir- sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology 2016; 63(2): 437-44.

17. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2,4, 5, and 6. N Engl J Med 2015; 373: 2599-607.

18. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017; 65: 426-38.

19. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-free Regimens. Gastroenterology 2016; 151: 70-86.